Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Operating Income (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Operating Income for 14 consecutive years, with -$17.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income rose 42.96% year-over-year to -$17.8 million, compared with a TTM value of -$90.7 million through Dec 2025, up 24.06%, and an annual FY2025 reading of -$90.7 million, up 24.06% over the prior year.
  • Operating Income was -$17.8 million for Q4 2025 at Karyopharm Therapeutics, down from -$15.2 million in the prior quarter.
  • Across five years, Operating Income topped out at $47.0 million in Q4 2021 and bottomed at -$52.4 million in Q1 2021.
  • Average Operating Income over 5 years is -$29.0 million, with a median of -$31.3 million recorded in 2023.
  • The sharpest move saw Operating Income surged 226.7% in 2021, then tumbled 172.12% in 2022.
  • Year by year, Operating Income stood at $47.0 million in 2021, then crashed by 172.12% to -$33.9 million in 2022, then fell by 11.63% to -$37.8 million in 2023, then grew by 17.26% to -$31.3 million in 2024, then surged by 42.96% to -$17.8 million in 2025.
  • Business Quant data shows Operating Income for KPTI at -$17.8 million in Q4 2025, -$15.2 million in Q3 2025, and -$24.4 million in Q2 2025.